Eurofins Genomics LLC, a leading player in the genomics industry, is headquartered in the United States and operates across major regions including Europe and Asia. Founded in 2000, the company has established itself as a trusted provider of high-quality genomic services, including DNA sequencing, gene synthesis, and oligonucleotide production. With a commitment to innovation, Eurofins Genomics stands out for its advanced technologies and rapid turnaround times, catering to a diverse clientele in research, pharmaceuticals, and biotechnology. The company has achieved significant milestones, including the expansion of its laboratory capabilities and the introduction of cutting-edge genomic solutions. Recognised for its reliability and expertise, Eurofins Genomics continues to strengthen its market position, making substantial contributions to the advancement of genomic research and applications.
How does Eurofins Genomics LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Eurofins Genomics LLC's score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eurofins Genomics LLC, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Eurofins Genomics may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, it will be essential for Eurofins Genomics to consider developing and communicating its climate commitments to align with global standards and expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Eurofins Genomics LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

